Evofem Inc.   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: San Diego CA United States (2009)

Organization Overview

First Clinical Trial
2011
NCT01306331
First Marketed Drug
2020
potassium bitartrate
First NDA Approval
2020
potassium bitartrate
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Evofem Inc. | EVOFEM INC

Active Ingredients

Marketed Drugs (3)

citric acid (2020)

lactic acid (2020)

potassium bitartrate (2020 NDA)

Drugs in Phase 3 Trials (5)

Key: Evofem Inc. (4) Acquired (1)

citric acid (2 trials)

lactic acid (3 trials)

nonoxynol-9 (Delfen) (2 trials)

potassium bitartrate (1 trial)

salmeterol (serevent) (13 trials)

Drugs in Phase 2 Trials (4)

Key: Evofem Inc. (1) Acquired (3)

fluticasone (cutivate) (6 trials)

isoprenaline (1 trial)

potassium hydrotartrate (1 trial)

prednisone (meticorten) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chlamydia Infections (Phase 3)

Gonorrhea (Phase 3)

Infections (Phase 2)

Sexually Transmitted Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 9